Member Info for Heimdal

My understanding is that this is a general rule for all listed companies where you have to demonstrate you have "sufficient level of operations and have assets of sufficient value to warrant its continuing listing". Back in 2012 we had US$145m in cash and listed sec, now we are running on fumes. I have noted a few companies being pulled up by HKSE for this during the last year or so where there was no mention of reverse take overs. One recent example 1102, China Candy might have been another - will need to check. At the end of the day we will have to generate some cash flow so Recordati will need to get on with it, not sure why the drag the chain on the OTC launch. A potential US partner might also look towards the EU for fairdinkum sales figures. Heimdal

Regent Pacific has a long history on the HKSE and it has been tough going since the company issued the 13c special dividend in early 2013 which was a major mistake. Profit warning after profit warning. We are still trading at historical lows (1.96c on pre con scale!) Maybe HK investors want to see positive sales figures from Europe? A major worry is if the exchange enforce Listing Rule 13.24, then we could be in real trouble. For now it looks like we are in the hands of the pip traders. We might need to generate serious cash flow to attract more serious long term investors. A lot of blue sky but Recordati will also need to hit it hard this year to get things moving. Heimdal

Bignose, if the share market was that predictable we would all be pip traders lol

Back at 19.5c, unbelievable.

Heimdal

Indeed, excellent news Dougie, re-rating overdue now!

Heimdal

You are right Italian, it appears to be a relatively minor pip trader, selling 1m blocks at 20c and buying 1m blocks back at 19c. SP bounced yesterday at the SMA(20) line and finished below the upper Bollinger band at 19.5c. The SP trend is upward, not in a straight line though lol

We must be due for an update on the OTC roll out progress in Europe soon, and possibly some news from the DLI front.
I am a bit puzzled as to why the company did not yet communicate to the market the roll out in Germany which IMO is SP price sensitive information - https://www.shop-apotheke.com/arzneimittel/16829031/fortacin-150-mg-ml-50-mg-ml.htm

Heimdal

Not sure about the 1.47m off screen sell but I did notice a number of 1m sell orders by Instinet in the Sell queue, first at 20.1c and then later at 20c. As soon as the 1m sell order was filled a new popped up automatically spooking the punters. Instinet back today with a 1m sell order sitting at 20c all day.

Morning Bignose, Instinet is NY based and the holder might expect short term market volatility given the political situation in the US. Current 575 sell depth is very thin, only obstacle is Instinet.
WRT US market research by Regent I think it is a smart inexpensive exercise - money well spent.

The automatic selling of 1m blocks at 20c by Instinet probably spooked buyers yesterday.
Instinet back with another 1m sell order at 20c this morning.
Interesting times in the US which could well be a trigger to affect the market in the short term.
The next week will be most interesting.

The market update was very well timed chart wise ;-) these guys are smart operators..
Yesterdays close above the upper Bollinger band was a good indication of things to come.
Happy days!

Heimdal

Strong finish today @ 19.3c above the upper Bollinger band. Chart looking very bullish with the cross over of the Slow Stochastic. I think we are due for the next wave now.

Heimdal

We need to break the 18.8/19c key resistance level. Bollinger bands, stochastics etc indicate upward break out is imminent.

Bignose, WRT to the strong dividend history you mentioned, my view is that the 13c special dividend back in 2013 was a major mistake as it left the company with hardly any cash, as such we ended up with the massive dilution in order to get PLE in the bag. Nonetheless, that is all history now and I am very hopeful for the future prospects of Regent Pacific. There is a lot going on at the moment with OTC in EU, FDA, potential commercial partner in USA, China, HK/Macao, Taiwan, ROW, DLI... frequent market updates etc. Happy days!

Senstend's™ market share in other markets to maintain a stable income for the Group and generate better returns for our shareholders."

Regent Pacific will receive US$ 5 million* (approximately HK$39 million) from Wanbang Pharmaceutical if the clinical study tentatively to be started in April/May 2021 meets its endpoints of determining the effects of Senstend™ on the Index of Premature Ejaculation (IPE) and the Intra-vaginal Ejaculation Latency Time (IELT) and to evaluate the safety and tolerability of Senstend™ in Premature Ejaculation subjects and their sexual partners, together with an import licence for Senstend™ granted by NMPA. Regent Pacific will also receive US$2 million* (approximately HK$15.6 million) upon the first commercial sale of Senstend™ in China from Wanbang Pharmaceutical with tiered percentage royalties on net sales, ranging from low to the high teens from first commercial sale.

In addition, Wanbang Pharmaceutical has ordered clinical supplies from Pharmaserve (North West) Limited ("PSNW"), the manufacturer of Senstend™/Fortacin™, with the aim of supplies being ready for the commencement of the clinical trial. Regent Pacific has also contracted PSNW to commence development on the commercial scale up to increase the current batch size per each manufacturing run to 50,000 units from 15,000 units. This is designed to meet Wanbang Pharmaceutical's requirements for China and Recordati's over-the-counter's requirements in the European Union and the United Kingdom.

Steady Progress in the United States

The Phase II validation study in the United States has been completed with 87 randomised subjects. The study is targeted to submit to the United States Food and Drug Administration ("FDA") during the first half of 2021. It is expected that the pivotal Phase III study could commence in the latter half of 2021, assuming the trial is sufficient to convince the FDA that the Premature Ejaculation Bothersome Evaluation Questionnaire serves as an appropriate measure for support of a label claim; with New Drug Application ("NDA") submission possible in late 2022, giving a Prescription Drug User Fee Act date at the end of 2023.

About Regent Pacific (Stock code: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 23 years of financial reporting since its initial public offering in May 1997.

About Fortacin™

Fortacin™ is the first solution to premature ejaculation (PE) that does not act on the central nervous system and offers bona fide therapeutic efficacy that has been validated through extensive clinical trials in Europe, with over 23,500 doses delivered to trial participants. The solution is a topical spray containing low doses of lidocaine and prilocaine

Regent Pacific Announces Key Progresses On FORTACIN(TM) / SENSTEND(TM) - Solution to Premature Ejaculation

Mon, January 4, 2021, 9:30 PM GMT+8·5 min read

CHINA

Regent Pacific received US$0.72 million (approximately HK$5.62 million, (net of 10% PRC withholding tax) from Wanbang Pharmaceutical on 29 December 2020

The Clinical Trial Approval ("CTA") will be obtained from the Center of Drug Evaluation by the end of Q1 2021

Regent Pacific to receive the following payments from Wanbang Pharmaceutical:

- US$3.20 million* (approximately HK$24.96 million) upon the successful approval from NMPA to commence the clinical trial

- US$ 5 million* (approximately HK$39 million) NMPA has granted import drug licence approval for Senstend™

- US$2 million* (approximately HK$15.6 million) upon first commercial sale of Senstend™ in China

*before deduction of PRC withholding tax

UNITED STATES

Phase II validation study has been completed with a total of 87 subjects being randomised and is target to submit the study to the United States Food and Drug Administration ("FDA") during the first half of 2021

HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK), a specialist healthcare, wellness and life sciences investment group is pleased to announce several key updates of Fortacin™ / Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on the central nervous system, in China and the United States respectively.

Regent Pacific received US$0.72 million (approximately HK$5.62 million) from its commercial strategic partner in China -Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. ("Wanbang Pharmaceutical"), a wholly controlled company of Shanghai Fosun Pharma to seek marketing approval of Senstend™ (the marketing name of Fortacin™ in China) in China on 29 December 2020. The Clinical Trial Approval ("CTA") of Senstend™ will be reviewed by the National Medical Products Administration ("NMPA") and is expected to be obtained from the Center of Drug Evaluation by the end of Q1 2021. Upon the successful approval from NMPA to commence the clinical trial, Regent Pacific will receive a payment of US$3.20 million* (approximately HK$24.96 million) from Wanbang Pharmaceutical.

Jamie Gibson, Chief Executive Officer of Regent Pacific, said, "We are delighted by this step toward full commercial approval of Senstend™ in China. Achieving this is a significant milestone which lays a solid foundation for marketing Senstend™ there in the near future."

Gibson added, "We are confident that this successful China initiative not only secures the world's largest market for Senstend™, but will also help us and our strategic partners to expand into other major markets such as the Middle East, India, North America and the Latin America (LATAM) region."

"Using the income generated by Senstend™ i

JAN 3, 2021: NEW Premature Ejaculation Treatment Market Study 2021-2026: Detailed analysis of current Industry figures with forecasts growth by regions-Absorption Pharmaceuticals, Bayer, Eli Lilly, Regent Pacific Group.

https://neighborwebsj.com/uncategorized/848976/premature-ejaculation-treatment-market-study-2021-2026-detailed-analysis-of-current-industry-figures-with-forecasts-growth-by-regions-absorption-pharmaceuticals-bayer-eli-lilly-regent-pacific-grou/

This is indeed excellent news Dougie - 36c might not be far away.
I hope you have loaded up the truck with cheap shares.
Heimdal

Thank you Bignose and Italian. 2021 should be a great year for Regent Pacific holders.

Chart looking very bullish with FDA, EU roll out and China news expected in the short term.
We have clearly turned the corner with frequent market updates. Profit warning end of Feb should not be major worry given the amortization of Fortacin during the last couple of years.

Where do you expect the share price to be at the end of this year? My guess is 36c and a MCap
around US$115 is not unrealistic by year end, possibly much faster.

Onward and upward.

Heimdal

Happy New Year all. Intetesting Bloomberg article here from DEC 29: Mainland Cash Chasing Hong Kong Stocks After Record Year.

Mainland investors have bought a net HK$666 billion ($86 billion) of the city’s shares, easily the most since both of Hong Kong’s trading links with onshore exchanges began operating in 2016. China’s increasing role in Hong Kong’s market could provide key support in years to come.

Companies in Hong Kong with relatively high growth potential such as Regent Oacific might well benefit from increased interest from mainland investors.

Moreover, Credit Suisse Group AG expects the Hang Seng Index to reach 30,000 points next year, 11% above current levels and last seen in mid-2019.

Heimdal

www.bloomberg.com/amp/news/articles/2020-12-29/mainland-cash-to-keep-chasing-hong-kong-stocks-after-record-year

Is this relevant to Regent Pacific? Are you running some kind of boiler room set up? Heimdal

Cheers, main thing is that FORTACIN is on the shelves in Germany now. Happy days!

I guess the options will be granted to Dr Wyllie as an early Christmas present for his FDA achievement?

Onwards and upwards!